Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancerFrancesco Caponigro, P. Fumoleau, Jakob B. Sørensen et al.|European Journal of Cancer|2002Cited by 28
A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgeryPatricia Pautier, Florence Duffaud|ESMO Open|2021Cited by 27